Sector News

Mylan CEO says still wants Perrigo but has other options

August 10, 2015
Life sciences
(Reuters) – Generic drugmaker Mylan Inc’s (MYL.O) chief executive said on Thursday that acquiring Perrigo Co (PRGO.N) was not a must and that it has other options should Perrigo successfully fend off Mylan’s $34 billion hostile offer.
 
However, Mylan CEO Heather Bresch said in an interview that getting the Perrigo deal done remains a top priority and that she still believes it can be completed by the end of this year.
 
If more than half of Mylan’s shareholders vote for the Perrigo transaction Aug. 28, the company will take its offer directly to Perrigo shareholders.
 
“With the Teva overhang and noise gone and Abbott, our largest shareholder, committing their stake to the Perrigo deal, that goes a long way to getting us to that 50.1 percent,” Bresch said in an interview. Abbott Laboratories holds more than 14 percent of Mylan shares.
 
Mylan, which itself had been fighting a takeover attempt by larger rival Teva Pharmaceutical Industries (TEVA.TA), got its wish to remain independent when Teva last week decided instead to buy Allergan’s (AGN.N) generics business for $40.5 billion.
 
Perrigo on Wednesday again said the $205 per share offer from Mylan substantially undervalues it, but Bresch said Mylan has no plan to sweeten its bid.
 
“We believe we have a fair and compelling offer on the table, so we’re not looking to change anything about the terms,” Bresch said.
 
“We’re as committed to it as we have ever been. We believe it is the right next transaction for our company,” Bresch said.
 
Ireland-based Perrigo would give Mylan over-the-counter consumer products, generic topical medicines and animal health offerings.
 
Bresch said Mylan, which is headquartered in the Netherlands after a tax inversion deal involving Abbott, has many options should the deal fall through.
 
“We like Perrigo, but we don’t have to have Perrigo,” Bresch told analysts earlier Thursday on a call to discuss quarterly results
 
“We’ve been actively looking at many targets out there,” she said of Mylan’s aim to become a leading consolidator in the generic drugs industry.
 
“Perrigo accelerates that for us,” she said. “We believe there’s a lot of different assets that can get us there. There are things for sale all over the globe.”
 
One asset that could become available is Pfizer’s (PFE.N) established products business. The drugmaker will decide by late 2016 whether to sell that unit.
 
“We absolutely would look at it,” Bresch said.
 
Mylan shares were up 1.1 percent at $55.21 on Nasdaq.
 
(Reporting by Bill Berkrot and Caroline Humer; Editing by Bernadette Baum, Bernard Orr)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”